ArticlePharmaceutical research2012
Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 45 citations in OpenAlex.
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Nanoemulsions a Delivery System in the Making for Tumor Targeting Therapeutics: Evaluation and Characterization to Meet Clinical Challenges.Current pharmaceutical biotechnology · 2025Review
- Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery.ACS omega · 2023Review
- Lipid-engineered nanotherapeutics for cancer management.Frontiers in pharmacology · 2023Review
- A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.PloS one · 2020Article
- Current Applications of Nanoemulsions in Cancer Therapeutics.Nanomaterials (Basel, Switzerland) · 2019Review
- Article
- EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.Pharmaceutical research · 2015Article
- Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases.The AAPS journal · 2015Review
- Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer.Pharmaceutical research · 2014Article
- Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy.AAPS PharmSciTech · 2014Review
- A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.American journal of translational research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOvarian cancer is a debilitating disease, which needs multi-pronged approach of targeted drug delivery and enhanced efficacy with the use of combination therapeutics. In this study, we have examined the anticancer activity of PIK75 incorporated in surface functionalized nanoemulsions for targeted delivery to SKOV-3 cells. A pro-apoptotic molecule C(6)-ceramide was also co-delivered to augment therapeutic efficacy.
methodsEGFR and FR functionalized nanoemulsions incorporating PIK75 and C(6)-ceramide were characterized for particle size, surface charge, entrapment efficiency and morphology. Fluorescence and quantitative uptake studies were conducted in SKOV-3 cells to determine intracellular distribution. Cell viability was assessed using MTT assay while mechanism of cytotoxicity was evaluated using capsase-3/7, TUNEL and hROS assay.
resultsCytotoxicity assay showed 57% decrease in IC(50) value of PIK75 following treatment with EGFR targeted nanoemulsion and 40% decrease following treatment with FR targeted nanoemulsion. Combination therapy with PIK75 and ceramide enhanced the cytotoxicity of PIK75 compared to therapy with individual formulations. The increase in cytotoxicity was attributed to increase in cellular apoptosis and hROS activity.
conclusionThe results of this study showed that the targeted system improved cytotoxicity of PIK75 compared to the non-targeted system. Combination therapy with ceramide augmented PIK75's therapeutic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.